MYLK-AS1 Enhances Glutamine Metabolism to Promote EGFR Inhibitor Resistance in Non–Small Cell Lung Cancer
MYLK-AS1 promotes resistance to EGFR inhibitors by inducing phase separation of ILF3 to stabilize GLUD1 and stimulate glutamine metabolism, highlighting this axis as a putative therapeutic target for overcoming resistance.
Authors
- Lei Song
- Xiyi Lu
- Tianyu Qu (ORCID: https://orcid.org/0000-0002-4242-0615)
- Chen Zhang
- Erbao Zhang (ORCID: https://orcid.org/0000-0002-5752-7976)
- Dandan Yin (ORCID: https://orcid.org/0000-0002-2550-5254)
- Jiali Dai (ORCID: https://orcid.org/0000-0002-4533-9185)
- Renhua Guo
- Jiali Xu (ORCID: https://orcid.org/0009-0001-2645-7223)
Institutions
- Nanjing University of Chinese Medicine (CN)
- Jiangsu Cancer Hospital (CN)
- Second Affiliated Hospital of Nanjing Medical University (CN)
- Nanjing Second Hospital (CN)
- Jiangsu Province Hospital (CN)
- Nanjing Medical University (CN)
Publication Details
- Journal
- Cancer Research
- Published
- 2025-05-14
- DOI
- https://doi.org/10.1158/0008-5472.can-23-3748
- Citations
- 6
- Primary Topic
- Cancer-related molecular mechanisms research
- Type
- article
- Field-Weighted Citation Impact
- 5.62